Study Design
This trial was designed as a single-center, open-label, nonrandomized,
parallel-group study. Ten healthy subjects with normal renal function,
defined by estimated glomerular filtration rate (eGFR) ≥ 90 mL/min/, and
10 subjects with severe renal impairment or
end-stage renal disease (eGFR ≤ 30
mL/min/) received a single oral dose of 0.5 g nemonoxacin capsule. eGFR
was calculated by the Chronic
Kidney Disease Epidemiology Collaboration equation.